AbbVie Inc. $ABBV Shares Bought by Union Bancaire Privee UBP SA

Union Bancaire Privee UBP SA grew its position in AbbVie Inc. (NYSE:ABBV) by 11.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 443,006 shares of the company’s stock after purchasing an additional 46,028 shares during the period. AbbVie accounts for 1.4% of Union Bancaire Privee UBP SA’s holdings, making the stock its 12th largest position. Union Bancaire Privee UBP SA’s holdings in AbbVie were worth $95,348,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ABBV. Diversified Trust Co grew its holdings in shares of AbbVie by 23.6% during the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after purchasing an additional 10,891 shares during the period. Permanent Capital Management LP purchased a new stake in AbbVie in the 3rd quarter valued at about $720,000. Railway Pension Investments Ltd lifted its position in AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after buying an additional 211,800 shares during the last quarter. World Investment Advisors boosted its stake in AbbVie by 9.4% during the third quarter. World Investment Advisors now owns 113,925 shares of the company’s stock worth $26,378,000 after buying an additional 9,811 shares during the period. Finally, Charles Schwab Trust Co increased its position in shares of AbbVie by 93.4% during the third quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock valued at $7,434,000 after acquiring an additional 15,502 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling

In related news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.25% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ABBV shares. Piper Sandler upped their price objective on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Citigroup cut their target price on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Royal Bank Of Canada initiated coverage on AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price target for the company. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Finally, UBS Group dropped their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie signed a multi‑year collaboration with Alloy Therapeutics to develop a next‑generation antibody discovery platform, which could expand AbbVie’s ability to find antibodies for targets current tech struggles with — a pipeline and long‑term revenue positive. AbbVie, Alloy Therapeutics Ink Deal to Develop Next‑Gen Antibody Platform
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) published global consumer research and new educational initiatives supporting evolving, multimodal aesthetic demand — a steadying, growth‑oriented business line that diversifies AbbVie beyond immunology. Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments
• Neutral Sentiment: Several market writeups note a recent share‑price pullback and discuss valuation after the selloff — useful for investors weighing whether the drop is a buying opportunity or a sign of longer‑term competitive risk. Assessing AbbVie (ABBV) Valuation After The Recent Share Price Pullback
• Negative Sentiment: Major negative catalyst — Johnson & Johnson’s Icotyde (first oral IL‑23 inhibitor) won FDA approval. An oral, once‑daily option raises convenience and pricing/market‑share questions for injectable Skyrizi, which has been AbbVie’s key growth driver. That approval is the main reason for the near‑term stock weakness. J&J wins FDA nod for psoriasis pill that aims to compete with top‑selling injections
• Negative Sentiment: Generic competition: Breckenridge launched a generic Milnacipran (Savella® equivalent), which can pressure revenue in the pain management segment where AbbVie previously sold Savella. Breckenridge announces launch of Milnacipran HCl Tablets, generic equivalent of Savella®

AbbVie Stock Down 1.0%

Shares of AbbVie stock opened at $206.32 on Friday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The company has a market capitalization of $364.80 billion, a P/E ratio of 87.42, a P/E/G ratio of 0.72 and a beta of 0.34. The company has a 50 day moving average of $223.41 and a 200 day moving average of $224.71.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the previous year, the firm posted $2.16 earnings per share. The company’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.4%. AbbVie’s payout ratio is presently 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.